-
Portfolio Company Yiviva CommencesInternational Phase IIb Liver Cancer Clinical TrialsRead Press Release -
Portfolio Company OncoheroesReceives Additional Investment and RecognitionRead Press Release -
Portfolio Company SciTechReceives FDA's Assent for Lymphoma Clinical TrialsRead Press Release -
Portfolio Company InterLeukin Combinatorial TherapiesReceives Matching Funds from Virginia CatalystRead Press Release
Women’s Venture Competition
The AIM-HI’s Women’s Venture Competition is a high-profile initiative among women-led oncology start-up companies or venture teams aspiring to soon establish firms. Learn more…
Accelerator Program
Most venture capital funds claim to engage in “active management,” while in fact doing little more than assuming passive board roles. AIM-HI is actively involved with each of its portfolio companies. Learn more…
Our Portfolio Companies
AIM-HI draws startups from the deep pipeline of National Foundation for Cancer Research (NFCR) funded scientists and the best-in-class global scientist-entrepreneur community. Learn more…
Our Mission
The AIM-HI Accelerator Fund is an independent 501(C)(3) non-profit organization, established with an initial grant from the National Foundation for Cancer Research with the vision to accelerate the translation of cancer drug discoveries by investing in seed-stage companies. It is a new paradigm through venture philanthropy to fund start-up oncology companies that commercialize innovative laboratory breakthroughs which can potentially save cancer patients’ lives.
Learn More About Us
Register to learn how charitable giving can help cancer startups cross the Valley of Death.